Alliancebernstein L.P. Neurocrine Biosciences Inc Transaction History

Alliancebernstein L.P.

$278 Billion
Q2 2024

A detailed history of Alliancebernstein L.P. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Alliancebernstein L.P. holds 621,865 shares of NBIX stock, worth $78.1 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

621,865

Previous 160,223 288.12%

Holding current value

$78.1 Million

Previous $22.1 Million 287.44%

% of portfolio

0.03%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $60.4 Million - $66.1 Million	461,642 Added 288.12%	621,865 $85.6 Million
Q1 2024 May 14, 2024	SELL	$130.4 - $143.74 $1.75 Million - $1.93 Million	-13,405 Reduced 7.72%	160,223 $22.1 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $2.64 Million - $3.3 Million	24,868 Added 16.72%	173,628 $22.9 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $1 Million - $1.25 Million	10,677 Added 7.73%	148,760 $16.7 Million
Q2 2023 Aug 15, 2023	SELL	$89.53 - $104.87 $1.19 Million - $1.39 Million	-13,266 Reduced 8.77%	138,083 $13 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $1.46 Million - $1.91 Million	-15,512 Reduced 9.3%	151,349 $15.3 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $1.25 Million - $1.49 Million	11,693 Added 7.54%	166,861 $19.9 Million
Q3 2022 Nov 15, 2022	BUY	$92.03 - $107.81 $601,968 - $705,185	6,541 Added 4.4%	155,168 $16.5 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $2.79 Million - $3.69 Million	-36,859 Reduced 19.87%	148,627 $14.5 Million
Q1 2022 May 13, 2022	BUY	$72.45 - $94.81 $1.59 Million - $2.08 Million	21,984 Added 13.45%	185,486 $17.4 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $617,128 - $822,992	-7,748 Reduced 4.52%	163,502 $13.9 Million
Q3 2021 Nov 10, 2021	BUY	$86.18 - $99.03 $1.58 Million - $1.81 Million	18,279 Added 11.95%	171,250 $16.4 Million
Q2 2021 Jul 30, 2021	SELL	$89.43 - $102.27 $534,344 - $611,063	-5,975 Reduced 3.76%	152,971 $14.9 Million
Q1 2021 May 06, 2021	BUY	$87.57 - $119.4 $8.82 Million - $12 Million	100,678 Added 172.78%	158,946 $15.5 Million
Q4 2020 Feb 08, 2021	SELL	$86.91 - $108.33 $55.6 Million - $69.3 Million	-639,914 Reduced 91.65%	58,268 $5.59 Million
Q3 2020 Nov 12, 2020	SELL	$96.16 - $135.15 $18.3 Million - $25.8 Million	-190,677 Reduced 21.45%	698,182 $67.1 Million
Q2 2020 Aug 13, 2020	SELL	$85.09 - $130.36 $20.8 Million - $31.9 Million	-244,961 Reduced 21.6%	888,859 $108 Million
Q1 2020 May 14, 2020	SELL	$75.11 - $113.76 $7.97 Million - $12.1 Million	-106,113 Reduced 8.56%	1,133,820 $98.1 Million
Q4 2019 Feb 18, 2020	SELL	$86.8 - $118.57 $928,933 - $1.27 Million	-10,702 Reduced 0.86%	1,239,933 $133 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $3.96 Million - $4.79 Million	47,231 Added 3.92%	1,250,635 $113 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $7.15 Million - $9.03 Million	98,945 Added 8.96%	1,203,404 $102 Million
Q1 2019 May 14, 2019	BUY	$69.31 - $91.53 $2.37 Million - $3.13 Million	34,243 Added 3.2%	1,104,459 $97.3 Million
Q4 2018 Feb 13, 2019	SELL	$68.32 - $124.36 $2.59 Million - $4.72 Million	-37,978 Reduced 3.43%	1,070,216 $76.4 Million
Q3 2018 Nov 08, 2018	SELL	$98.88 - $125.85 $5.61 Million - $7.14 Million	-56,706 Reduced 4.87%	1,108,194 $136 Million
Q2 2018 Aug 13, 2018	SELL	$75.3 - $105.99 $8,132 - $11,446	-108 Reduced 0.01%	1,164,900 $114 Million
Q1 2018 May 14, 2018	BUY	$75.88 - $92.43 $16.4 Million - $19.9 Million	215,680 Added 22.72%	1,165,008 $96.6 Million
Q4 2017 Feb 13, 2018	SELL	$58.53 - $77.59 $3.3 Million - $4.37 Million	-56,319 Reduced 5.6%	949,328 $73.7 Million
Q3 2017 Nov 13, 2017	BUY	$47.97 - $61.28 $48.2 Million - $61.6 Million	1,005,647	1,005,647 $61.6 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Neurocrine Biosciences Inc Transaction History